Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Cellegy targets women and testosterone

Many biotech companies choose their drug projects based on unmet medical needs, making the potential market largely a question of patient population and market penetration. By contrast, Cellegy Pharmaceuticals Inc. is starting a Phase I trial with its Tostrelle transdermal testosterone gel

Read the full 429 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers